ArticleDiagnostic pathology2014
Myofibroblastic reaction is a common event in metastatic disease of breast carcinoma: a descriptive study.
Article in Diagnostic pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 7 citations in OpenAlex.
- Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast.Discover oncology · 2026Article
- Quantification of stromal reaction in breast carcinoma and its correlation with tumor grade and free progression survival.PloS one · 2019Article
- Expression of the glucocorticoid receptor in breast cancer-associated fibroblasts.Molecular and clinical oncology · 2016Article
- Article
- Stromal expression of matrix metalloproteinase 2 in cancer-associated fibroblasts is strongly related to human epidermal growth factor receptor 2 status in invasive breast carcinoma.Molecular and clinical oncology · 2016Article
- Relationship between ultrasound elastography and myofibroblast distribution in breast cancer and its clinical significance.Scientific reports · 2016Article
- Macrophage migration inhibitory factor involvement in breast cancer (Review).International journal of oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe modification of stromal components with the disappearance of CD34 positive fibrocytes and by contrast the acquisition of smooth-muscle actin positive myofibroblasts is a frequent event in breast carcinomas but has been little studied in its metastatic sites. Therefore, the aim of the present study is to examine the stromal expression of CD34 and SMA in lymph node and liver metastases which are two of the most frequent metastatic breast cancer sites.
methodsThe distribution of CD34 fibrocytes and SMA myofibroblasts has been studied by immunohistochemistry in 41 lymph node and 36 liver metastases from patients with invasive carcinoma of no special type.
resultsNo CD 34 fibrocytes were noted in the stroma of metastasis. By contrast, smooth-muscle actin stromal expression was observed in 95.1% of lymph node and 97.2% of liver metastases, independently of histological features of tumours.
conclusionsMyofibroblasts represent a major and constant component in the metastatic tumoral stroma of breast carcinoma highlighting that these cells could play an active role in tumour cells proliferation and spread. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_196.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.